PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50119C00075Eo14042 botulism antitoxin — Emergent Biosolutions Canada Inc

Emergent Biosolutions Canada Inc holds $355.5M across 2 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Mar 30, 2027 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Emergent Biosolutions Canada Inc

Recipient

Mar 30, 2027

PoP end

$270.9M

Obligated

325412

NAICS

6505

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Emergent Biosolutions Canada Inc — $90

Contract facts

NONE

Contract number75A50119C00075

AgencyBarda - Aspr / Daappo / Barda Dcma

Awarding officeBarda - Aspr / Daappo / Barda Dcma

IncumbentEmergent Biosolutions Canada Inc

UEIXM23STFMVML6

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Related solicitation75A50119R00046

PoP end (current)Mar 30, 2027

PoP end (w/ options)Sep 29, 2029

Obligated$270.9M

EO14042 BOTULISM ANTITOXIN is a federal NONE award for Barda - Aspr / Daappo / Barda Dcma held by Emergent Biosolutions Canada Inc. Estimated value $320.9M ($270.9M obligated). Current period of performance ends Mar 30, 2027 (potential Sep 29, 2029). Last award drew 1 bidder. Related solicitation 75A50119R00046.

Recompete timing

Public

● Expiring in 205 days

Current PoP ends Mar 30, 2027 (205 days remaining). Agencies typically plan 12–18 months ahead — at 6.7 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Emergent Biosolutions Canada Inc — $355.5M obligated across 2 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$355.5M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50119C00075?

75A50119C00075 (Eo14042 botulism antitoxin) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $320.9M, currently held by Emergent Biosolutions Canada Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50119C00075?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50119C00075 to Emergent Biosolutions Canada Inc.

Who is the incumbent on 75A50119C00075?

Emergent Biosolutions Canada Inc is the incumbent with $355.5M across 2 related awards in SCOUT’s public footprint. The current period of performance ends Mar 30, 2027.

When does Emergent Biosolutions Canada Inc’s 75A50119C00075 come up for recompete?

SCOUT tracks a period-of-performance end of Mar 30, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75A50119C00075 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action May 27, 2026